Arbutus Biopharma (ABUS) Cash from Financing Activities (2013 - 2026)

Arbutus Biopharma has reported Cash from Financing Activities for 14 years, with the latest figure at $11.6 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 317.35% year-over-year to $11.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.6 million (down 52.04% YoY) and the FY2025 annual result came in at $5.7 million, down 89.0% from the prior year.
• Cash from Financing Activities rose to $11.6 million in Q1 2026 per ABUS's latest filing, from $1.6 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $24.4 million in Q1 2024 and troughed at $113000.0 in Q2 2022.
• A 5-year average of $7.8 million and a median of $3.8 million in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities soared 4096.46% in 2023, then slumped 98.14% in 2025.
• Over 5 years, Cash from Financing Activities stood at $11.1 million in 2022, then sank by 65.65% to $3.8 million in 2023, then plunged by 62.67% to $1.4 million in 2024, then grew by 15.41% to $1.6 million in 2025, then surged by 608.48% to $11.6 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $11.6 million, $1.6 million, and $844000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.